Candidates: Antibodies bioengineered to fight COVID-19
Type: Broadly neutralizing antibodies based on the company’s SuperHuman platform, which according to the company is the world’s most advanced computationally optimized human antibody library for antibody discovery.
Status: Distributed Bio’s CEO, president, and chairman Jacob Glanville, PhD, wrote April 2 that after nine weeks using its Tumbler technology, the company has generated thousands of extremely potent picomolar antibody binders that block known neutralizing ACE2 epitopes, blocking the SARS-CoV-2 from infecting human cells. “Hundreds of potent candidate therapeutic antibodies discovered that block the ACE2 receptor interaction with virus,” Distributed stated in a presentation.
A day earlier in a series of tweets, Glanville said the company’s approach was a “candidate cure” for COVID-19, and added: “We are trying to get this out by September but it will need funding and efficient GMP manufacturing.” That earned the company attention from news outlets as varied as Yahoo! Finance, Fox News Channel, and Radio New Zealand.
In March, Glanville told a South Korean outlet that the company is working to extract five SARS-CoV-2 antibodies and mutate them into 1 billion different types to see whether any of the antibodies bind to the virus that causes COVID-19.
If a potential antibody is identified this month, it could be mass produced in August or September, said Glanville, who gained fame after being featured in the Netflix docu-series “Pandemic: How to Prevent an Outbreak” in January.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: